Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domvanalimab + zimberelimab + chemotherapy versus pembrolizumab + chemotherapy as first-line treatment for metastatic NSCLC without EGFR or ALK alterations
CTR20240963Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of domvanalimab, zimberelimab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Gilead Sciences. Started Apr 2024; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240963.